The global market for In-Vivo CRO was valued at US$4.6 Billion in 2024 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 7.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the In-Vivo CRO market.
The rising complexity of therapeutics - including biologics, gene therapies, and personalized medicines - requires more sophisticated animal testing protocols that many in-house facilities cannot adequately support. In-vivo CROs offer customized study designs, validated models for specific disease indications, and advanced imaging and telemetry capabilities. Their ability to manage genetically engineered animal models, conduct toxicology studies, and support investigational new drug (IND) submissions makes them indispensable partners in preclinical research pipelines.
CROs are also expanding their portfolios to include specialized disease models - such as oncology, autoimmune disorders, rare diseases, and CNS pathologies - tailored to meet the evolving needs of biopharma companies. The development of humanized mouse models and transgenic strains has made it possible to conduct more translational research, bridging the gap between animal and human responses. Integration of digital lab notebooks, automated data capture systems, and AI-based data analysis tools is further increasing operational efficiency and scientific accuracy across in-vivo studies.
North America dominates the global in-vivo CRO market, supported by a robust biopharmaceutical R&D ecosystem, established regulatory frameworks, and a high concentration of contract research infrastructure. Europe follows closely, with strong demand across Germany, the UK, and France. Asia-Pacific is emerging as a high-growth region, led by China and India, where cost advantages, regulatory reforms, and expanding local biopharma sectors are attracting outsourcing activity. Additionally, growing interest in ethical animal research and adherence to Good Laboratory Practice (GLP) standards in these regions is helping align local CROs with global clients’ expectations.
In parallel, advances in non-invasive imaging, telemetry, and disease model customization are enhancing the value proposition of in-vivo CROs, making them strategic partners in early-stage decision-making. Regulatory emphasis on well-documented, ethically conducted animal studies - especially for IND filings - continues to reinforce the importance of standardized, GLP-compliant service providers. Furthermore, the increasing demand for personalized and orphan drugs is creating a need for more targeted and adaptable in-vivo studies. These combined factors are ensuring steady and sustained growth of the in-vivo CRO market as a critical enabler of modern drug discovery and development.
Segments: Type of Molecule (Small Molecules, Large Molecules); Therapeutic Area (Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions, Other Therapeutic Areas); Service Type (Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services, Other Service Types).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global In-Vivo CRO Market - Key Trends & Drivers Summarized
Why Are In-Vivo CRO Services Gaining Strategic Importance in Drug Development?
In-vivo contract research organizations (CROs) play a critical role in the pharmaceutical and biotechnology industries by providing outsourced preclinical and early-stage research services involving live animal models. These studies are essential to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of drug candidates before progressing to human trials. As regulatory scrutiny and drug development costs rise, sponsors are increasingly turning to specialized in-vivo CROs for their technical expertise, regulatory knowledge, and capacity to accelerate timelines while ensuring scientific rigor.The rising complexity of therapeutics - including biologics, gene therapies, and personalized medicines - requires more sophisticated animal testing protocols that many in-house facilities cannot adequately support. In-vivo CROs offer customized study designs, validated models for specific disease indications, and advanced imaging and telemetry capabilities. Their ability to manage genetically engineered animal models, conduct toxicology studies, and support investigational new drug (IND) submissions makes them indispensable partners in preclinical research pipelines.
How Are Technology and Specialization Advancing the Capabilities of In-Vivo CROs?
Technological innovation is reshaping the landscape of in-vivo research services, enabling CROs to deliver higher accuracy, reproducibility, and insight into complex biological responses. Real-time imaging technologies such as MRI, PET, and optical imaging allow for non-invasive monitoring of disease progression and therapeutic impact. Advanced telemetry systems enable continuous measurement of vital signs, behavioral changes, and physiological parameters, reducing the number of animals required while improving data quality.CROs are also expanding their portfolios to include specialized disease models - such as oncology, autoimmune disorders, rare diseases, and CNS pathologies - tailored to meet the evolving needs of biopharma companies. The development of humanized mouse models and transgenic strains has made it possible to conduct more translational research, bridging the gap between animal and human responses. Integration of digital lab notebooks, automated data capture systems, and AI-based data analysis tools is further increasing operational efficiency and scientific accuracy across in-vivo studies.
Which Segments and Regions Are Driving the Expansion of the In-Vivo CRO Market?
Pharmaceutical and biotechnology companies are the primary clients fueling demand for in-vivo CRO services, especially mid-size and emerging biotech firms that rely heavily on external partners due to limited internal R&D infrastructure. Increasing demand is also seen from academic research institutions and government-sponsored initiatives focused on translational medicine, vaccine development, and rare disease research. The oncology and CNS therapeutic areas represent the largest application segments, owing to the extensive animal modeling required to study tumor behavior and neurological functions.North America dominates the global in-vivo CRO market, supported by a robust biopharmaceutical R&D ecosystem, established regulatory frameworks, and a high concentration of contract research infrastructure. Europe follows closely, with strong demand across Germany, the UK, and France. Asia-Pacific is emerging as a high-growth region, led by China and India, where cost advantages, regulatory reforms, and expanding local biopharma sectors are attracting outsourcing activity. Additionally, growing interest in ethical animal research and adherence to Good Laboratory Practice (GLP) standards in these regions is helping align local CROs with global clients’ expectations.
The Growth in the In-Vivo CRO Market Is Driven by Several Factors…
It is driven by the increasing complexity of drug candidates, which necessitates advanced animal modeling to evaluate safety and efficacy prior to clinical trials. Biopharmaceutical companies are increasingly outsourcing in-vivo studies to reduce fixed R&D costs, access specialized expertise, and accelerate timelines in competitive therapeutic areas. The expanding pipeline of biologics, cell and gene therapies, and novel delivery systems further amplifies the need for sophisticated in-vivo capabilities that can simulate human-like responses.In parallel, advances in non-invasive imaging, telemetry, and disease model customization are enhancing the value proposition of in-vivo CROs, making them strategic partners in early-stage decision-making. Regulatory emphasis on well-documented, ethically conducted animal studies - especially for IND filings - continues to reinforce the importance of standardized, GLP-compliant service providers. Furthermore, the increasing demand for personalized and orphan drugs is creating a need for more targeted and adaptable in-vivo studies. These combined factors are ensuring steady and sustained growth of the in-vivo CRO market as a critical enabler of modern drug discovery and development.
Report Scope
The report analyzes the In-Vivo CRO market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Type of Molecule (Small Molecules, Large Molecules); Therapeutic Area (Oncology, Cardiology, Diabetes, Autoimmune / Inflammation Conditions, Infectious Diseases, CNS Conditions, Other Therapeutic Areas); Service Type (Preclinical Testing, Clinical Research Services, Laboratory Services, Consulting Services, Other Service Types).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Small Molecules segment, which is expected to reach US$5.1 Billion by 2030 with a CAGR of a 9.0%. The Large Molecules segment is also set to grow at 5.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $1.2 Billion in 2024, and China, forecasted to grow at an impressive 12.4% CAGR to reach $1.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global In-Vivo CRO Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global In-Vivo CRO Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global In-Vivo CRO Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Biocytogen, Charles River Laboratories, Clinipace (Caidya), Covance Inc., Crown Bioscience and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 39 companies featured in this In-Vivo CRO market report include:
- Biocytogen
- Charles River Laboratories
- Clinipace (Caidya)
- Covance Inc.
- Crown Bioscience
- Eurofins Scientific
- Evotec SE
- GemPharmatech Co., Ltd.
- ICON plc
- IQVIA Inc.
- Janvier Labs
- Labcorp Drug Development
- Parexel International Corporation
- Pharmaceutical Product Development (PPD)
- PsychoGenics Inc.
- Syneos Health
- Taconic Biosciences, Inc.
- The Jackson Laboratory
- Thermo Fisher Scientific Inc.
- WuXi AppTec
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biocytogen
- Charles River Laboratories
- Clinipace (Caidya)
- Covance Inc.
- Crown Bioscience
- Eurofins Scientific
- Evotec SE
- GemPharmatech Co., Ltd.
- ICON plc
- IQVIA Inc.
- Janvier Labs
- Labcorp Drug Development
- Parexel International Corporation
- Pharmaceutical Product Development (PPD)
- PsychoGenics Inc.
- Syneos Health
- Taconic Biosciences, Inc.
- The Jackson Laboratory
- Thermo Fisher Scientific Inc.
- WuXi AppTec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 387 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 4.6 Billion |
| Forecasted Market Value ( USD | $ 7.2 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
